SCHEMBL27372

SCHEMBL27372

CCC(O[C]=O)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.42
MIF P14174 1/20 0.39
IGLV6-57 P01721 1/20 0.38
POLB P06746 2/20 0.37
GSR P00390 1/20 0.37
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
SLC6A4 P31645 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
ALKBH1 Q13686 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
PKM P14618 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
HSD17B10 Q99714 1/20 0.35
SLC7A5 Q01650 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21835014 0.85 MAPT (0.38) LMNAPOLBKMT2AMEN1SMN1; SMN2
SCHEMBL1432767 0.85 AOC3 (0.39) LMNAPOLBGSRKMT2AMEN1
SCHEMBL4670361 0.82 ALDH1A1 (0.37) LMNAKMT2AMEN1SLC6A4SMN1; SMN2
SCHEMBL6003373 0.82 POLB (0.42) LMNAPOLBSLC6A4SMN1; SMN2SLC7A5
SCHEMBL5515058 0.81 CYP17A1 (0.39) LMNAPOLBKMT2ASLC6A4SMN1; SMN2
SCHEMBL3928059 0.80 SLC7A5 (0.40) LMNAPOLBSMN1; SMN2SLC7A5KDM4E
SCHEMBL21632633 0.80 LMNA (0.42) LMNAMIFIGLV6-57KMT2AMEN1
SCHEMBL11480147 0.80 GSR (0.37) LMNAPOLBGSRKMT2ASLC6A4
SCHEMBL6716961 0.79 ALDH1A1 (0.40) POLBSMN1; SMN2SLC7A5ALDH1A1
SCHEMBL6723179 0.79 ALDH1A1 (0.40) POLBSMN1; SMN2SLC7A5ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 529 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024112705-A1 BORONIC ACID AND BORONATE COMPOSITIONS AND METHODS ELIMA THERAPEUTICS, INC. (US) 2024-05-30 WO claimed
EP-2758389-B1 PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS MERCK SHARP & DOHME (US) 2017-06-07 EP claimed
US-9394282-B2 Pyrazole carboxamides as Janus kinase inhibitors MERCK SHARP & DOHME CORP. (US) 2016-07-19 US claimed
US-20140235641-A1 PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS INTERVET INC. 2014-08-21 US claimed
US-6762180-B1 Substituted indolines which inhibit receptor tyrosine kinases BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-07-13 US claimed
EP-1206446-B1 CARBOXYLIC ACID AMIDES, THEIR PRODUCTION AND THEIR USE AS DRUGS BOEHRINGER INGELHEIM PHARMA (DE) 2004-05-26 EP claimed
EP-1322608-A1 DELTA1-PYRROLINES USED AS PESTICIDES Bayer CropScience AG (DE) 2003-07-02 EP claimed
WO-2002024646-A1 DELTA1-PYRROLINES USED AS PESTICIDES BAYER CROPSCIENCE AG (DE) 2002-03-28 WO claimed
WO-2024112705-A1 BORONIC ACID AND BORONATE COMPOSITIONS AND METHODS ELIMA THERAPEUTICS, INC. (US) 2024-05-30 WO disclosed
US-20240156792-A1 COMBINATION THERAPY USING AZABICYCLO COMPOUND FOR CANCER TAIHO PHARMACEUTICAL CO., LTD. (JP) 2024-05-16 US disclosed
WO-2024075815-A1 8-HYDROXYQUINOLINE COMPOUND AND USE THEREOF 国立大学法人大阪大学 2024-04-11 WO disclosed
US-11918562-B2 Combination therapy using azabicyclo compound for cancer TAIHO PHARMACEUTICAL CO., LTD. (JP) 2024-03-05 US disclosed
WO-2024033845-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-02-15 WO disclosed
CN-113993719-B Trisulfide compound 住友化学株式会社 2024-01-02 CN disclosed
US-4220647-A MUSCLE RELAXANTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1980-09-02 US disclosed
US-4181800-A ANTIBIOTICS FROM SUBSTITUTED PERHYDRO-S-TRIAZINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1980-01-01 US disclosed
US-4108861-A Azetothiazole-5-yl-3-halomethyl-2-butenoic acid derivatives and the preparation of 5-thia-1-azabicyclo-[4.2.0]-2-octene-2-carboxylic acid derivatives from them FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1978-08-22 US disclosed
US-4057550-A 14,15-DIHYDRO-14-CYANO-EBURNAMENINES, VASODILATION RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 1977-11-08 US disclosed
US-4054571-A Nitrogen-containing polycyclic compounds and a process for the preparation thereof RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 1977-10-18 US disclosed
US-3933859-A BLOOD PRESSURE LOWERING, SYMPATHECTOMY HOFFMANN-LA ROCHE, INC. (US) 1976-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240156792-A1 COMBINATION THERAPY USING AZABICYCLO COMPOUND FOR CANCER HSP90AB1, HSP90AA1, HSP90AB2P LMNA 4736/4885MIF 3740/4885IGLV6-57 4770/4885
US-11918562-B2 Combination therapy using azabicyclo compound for cancer HSP90AB1, HSP90AA1, HSP90AB2P LMNA 4736/4885MIF 3740/4885IGLV6-57 4770/4885
US-20140235641-A1 PYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS JAK1, JAK3, JAK2 LMNA 4840/4885MIF 948/4885IGLV6-57 1726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.